Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.31 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | WEE1 | P30291 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934603 | 0.89 | AURKA (0.34) | EIF4A1PGRMEN1ALDH1A1MAPT | |
| SCHEMBL6113483 | 0.86 | EIF4A1 (0.32) | EIF4A1 | |
| SCHEMBL9933382 | 0.85 | PGR (0.30) | PGR | |
| SCHEMBL9933967 | 0.85 | PGR (0.30) | PGR | |
| SCHEMBL29664183 | 0.85 | PGR (0.34) | PGRMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL1680041 | 0.85 | PGR (0.34) | PGRMEN1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL8772740 | 0.85 | EIF4A1 (0.32) | EIF4A1 | |
| SCHEMBL9932623 | 0.85 | KDM4E (0.36) | PGRMEN1ALDH1A1MAPTCYP2C9 | |
| SCHEMBL25606724 | 0.85 | KDM4E (0.36) | PGRMEN1ALDH1A1MAPTCYP2C9 | |
| SCHEMBL29664129 | 0.84 | PGR (0.32) | EIF4A1PGRMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651914-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-05-13 | — | — | EP | claimed |
| US-8920928-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2014-12-30 | — | — | US | claimed |
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | US | claimed |
| EP-2651914-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8920928-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8920928-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8920928-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2651914-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082999-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082999-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | CRY2, CRY1, IPO4 | HTR6 855/4885EIF4A1 2797/4885PGR 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.